Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | GSK3B | P49841 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595170 | 0.97 | SCN9A (0.95) | SCN9AMAPTGSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL30450684 | 0.90 | SCN9A (0.82) | SCN9AMAPTGSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL22797745 | 0.90 | SCN9A (0.82) | SCN9AMAPTGSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL22797774 | 0.88 | SCN9A (0.79) | SCN9ASMN1; SMN2ALDH1A1PPARGGPR52 | |
| SCHEMBL22799218 | 0.88 | SCN9A (0.79) | SCN9AMAPTGSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL30450680 | 0.87 | SCN9A (0.77) | SCN9ASMN1; SMN2ALDH1A1PPARGGPR52 | |
| SCHEMBL20595173 | 0.87 | SCN9A (0.77) | SCN9ASMN1; SMN2ALDH1A1PPARGGPR52 | |
| SCHEMBL22798408 | 0.87 | SCN9A (0.77) | SCN9AMAPTGSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL22798213 | 0.87 | SCN9A (1.00) | SCN9AMAPTGSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL22798215 | 0.87 | SCN9A (0.77) | SCN9AMAPTGSK3BSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | claimed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | claimed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | SCN9A 9/4885MAPT 2729/4885GSK3B 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.